11 reports of this reaction
1.9% of all ANTIFUNGAL LIQUID SPRAY reports
#6 most reported adverse reaction
BRONCHOPULMONARY ASPERGILLOSIS is the #6 most commonly reported adverse reaction for ANTIFUNGAL LIQUID SPRAY, manufactured by ARMY & AIR FORCE EXCHANGE SERVICE. There are 11 FDA adverse event reports linking ANTIFUNGAL LIQUID SPRAY to BRONCHOPULMONARY ASPERGILLOSIS. This represents approximately 1.9% of all 575 adverse event reports for this drug.
Patients taking ANTIFUNGAL LIQUID SPRAY who experience bronchopulmonary aspergillosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BRONCHOPULMONARY ASPERGILLOSIS is a less commonly reported adverse event for ANTIFUNGAL LIQUID SPRAY, but still significant enough to appear in the safety profile.
In addition to bronchopulmonary aspergillosis, the following adverse reactions have been reported for ANTIFUNGAL LIQUID SPRAY:
The following drugs have also been linked to bronchopulmonary aspergillosis in FDA adverse event reports:
BRONCHOPULMONARY ASPERGILLOSIS has been reported as an adverse event in 11 FDA reports for ANTIFUNGAL LIQUID SPRAY. This does not prove causation, but indicates an association observed in post-market surveillance data.
BRONCHOPULMONARY ASPERGILLOSIS accounts for approximately 1.9% of all adverse event reports for ANTIFUNGAL LIQUID SPRAY, making it a notable side effect.
If you experience bronchopulmonary aspergillosis while taking ANTIFUNGAL LIQUID SPRAY, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.